Haemonetics Competitors
| HAE Stock | USD 57.76 0.12 0.21% |
Haemonetics vs Burning Rock Correlation
Excellent diversification
The correlation between Haemonetics and BNR is -0.62 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Haemonetics and BNR in the same portfolio, assuming nothing else is changed.
Moving together with Haemonetics Stock
Moving against Haemonetics Stock
| 0.83 | HYB | HOYA | PairCorr |
| 0.68 | VREX | Varex Imaging Corp | PairCorr |
| 0.65 | EDAP | EDAP TMS SA | PairCorr |
| 0.6 | EKSO | Ekso Bionics Holdings | PairCorr |
| 0.53 | ECOR | Electrocore LLC | PairCorr |
Haemonetics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Haemonetics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Haemonetics and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Haemonetics does not affect the price movement of the other competitor.
| 0.31 | 0.24 | 0.68 | 0.77 | -0.72 | IINN | ||
| 0.31 | -0.37 | 0.32 | 0.57 | -0.43 | PTHL | ||
| 0.24 | -0.37 | 0.28 | -0.22 | -0.02 | BMRA | ||
| 0.68 | 0.32 | 0.28 | 0.6 | -0.5 | SSKN | ||
| 0.77 | 0.57 | -0.22 | 0.6 | -0.79 | APVO | ||
| -0.72 | -0.43 | -0.02 | -0.5 | -0.79 | BNR | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Haemonetics Stock performing well and Haemonetics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Haemonetics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IINN | 3.07 | (0.84) | 0.00 | (0.68) | 0.00 | 6.52 | 15.61 | |||
| PTHL | 5.52 | 0.37 | 0.03 | (0.31) | 6.77 | 6.56 | 136.77 | |||
| BMRA | 2.63 | (0.11) | 0.00 | (0.09) | 0.00 | 6.02 | 18.44 | |||
| SSKN | 4.64 | (1.84) | 0.00 | (0.41) | 0.00 | 7.56 | 78.88 | |||
| APVO | 4.70 | (2.00) | 0.00 | (1.34) | 0.00 | 7.81 | 43.37 | |||
| BNR | 7.88 | 1.64 | 0.22 | 0.58 | 6.84 | 18.91 | 50.29 |
Cross Equities Net Income Analysis
Compare Haemonetics and related stocks such as Inspira Technologies Oxy, Pheton Holdings, and Biomerica Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IINN | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (4.6 M) | (7.2 M) | (17 M) | (4 M) | (11.3 M) | (11.1 K) | (9.9 K) | (10.4 K) |
| BMRA | (1.9 M) | 548.4 K | 537 K | (215.7 K) | (331.4 K) | (1.5 M) | (908.6 K) | (1.5 M) | (2.4 M) | (2.3 M) | (7.4 M) | (4.5 M) | (7.1 M) | (6 M) | (5 M) | (4.5 M) | (4.3 M) |
| SSKN | (2.3 M) | (20.4 M) | (22.7 M) | (25.9 M) | (16 M) | (27.9 M) | (3.3 M) | (21.5 M) | (4 M) | (3.8 M) | (4.4 M) | (2.7 M) | (5.5 M) | (10.8 M) | (10.1 M) | (9.1 M) | (9.5 M) |
| APVO | (53.3 M) | (53.3 M) | (53.3 M) | (53.3 M) | (51.1 M) | (59.3 M) | (112.4 M) | 7 M | (53.7 M) | (44.7 M) | (17.8 M) | (27.3 M) | 8 M | (17.4 M) | (24.1 M) | (27.7 M) | (29.1 M) |
| BNR | (131.3 M) | (131.3 M) | (131.3 M) | (131.3 M) | (131.3 M) | (131.3 M) | (131.3 M) | (131.3 M) | (177.5 M) | (168.3 M) | (407.2 M) | (796.7 M) | (971.2 M) | (653.7 M) | (346.6 M) | (312 M) | (327.6 M) |
Haemonetics and related stocks such as Inspira Technologies Oxy, Pheton Holdings, and Biomerica Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Haemonetics financial statement analysis. It represents the amount of money remaining after all of Haemonetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Haemonetics Competitive Analysis
The better you understand Haemonetics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Haemonetics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Haemonetics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Haemonetics Competition Performance Charts
Five steps to successful analysis of Haemonetics Competition
Haemonetics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Haemonetics in relation to its competition. Haemonetics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Haemonetics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Haemonetics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Haemonetics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Haemonetics position
In addition to having Haemonetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Haemonetics Correlation with its peers. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Health Care Equipment & Supplies sector continue expanding? Could Haemonetics diversify its offerings? Factors like these will boost the valuation of Haemonetics. Market participants price Haemonetics higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Haemonetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.284 | Earnings Share 3.63 | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Haemonetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.